Active Lifestyler, Villager, Entrepreneur, and more recently a Cancer Super-Responder. One of the 1% of the 1% of all cancer survivors. A passionate road cyclist, runner, and avid reader.
“Having your passion & purpose aligned creates a conduit for your willingness to rise up from within. This alignment gives oxygen to your dreams, visions, and aspirations, it provides a pathway toward their outward and tangible reality.” –Steve–
Steve has for over 25 years specialized in developing urban retail and industrial village environments. In recent years due to a succession of unexpected health challenges, he evolved this experience to include targeted information technology – “Smart Localism” and developing Smart Villager Community ecosystems have risen up from this.
November 2016, Steve was given a terminal cancer diagnosis (Liver /Pancreatic) with less than 6 months to live. He then endured 25 hours of significant surgeries to remove multiple organs, but the cancer continued to spread throughout his liver and lungs. At stage 4 and metastatic he was thrown a “Hail Mary Pass” by Dr Matthew Burge and Merck in California. With only weeks if not days to live Steve became a super responder, “one of the 1% of the 1%.” of all cancer survivors. Stunningly, it took just 3 days to respond, and he became a part of the cancer cure equation. Steve became Merck’s second-ever patient to survive and fully clear a metastatic stage 4 Cholangiocarcinoma.
“When you face drawing your last breath, you see what you are losing, you see what you did not see before, you see what others cannot. Regardless of the finiteness of this, you can still choose to act or not, on what you have seen and learned. I was more than fortunate, I get to continue on with what I have learned.” –Steve–
Lemons to Lemonade
Now equipped with a very intimate knowledge of cancer mutations and targeted therapies, Steve began developing a world-first, Peer to Peer Mutational Match Making platform. (ie Mutational Tinder) where Patients from anywhere on the globe can connect and potentially meet. Patients are matched by their specific genomic mutation or combination of mutations. This idea was the result of multiple patients contacting Steve due to his cancer and mutation type – they wanted to learn and share, to increase their own survival chances.
Dr. James Allison’s (2018 Nobel Prize winner) Checkpoint pathway inhibitor breakthrough, turned fiction into fact. A truly amazing “penicillin moment” in modern medical history. It opened up a landscape of Molecular and genomic profiling of the patient’s biopsy (tissue sample) using NGS – Next-Gen Sequencing. It created a road map and a torchlight to target and eliminate the exact mutation causing creating the cancer growth.